Bortezomib and Waldenstrom's macroglobulinemia

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 5, 2009, Pages 909-916

  Pascal, Laurent ^a   Gay, Julie ^a   Willekens, Christophe ^a   Wemeau, Mathieu ^a   Balkaran, Sandy ^a   Robu, Daniela ^a   Roccaro, Aldo ^a   Morel, Pierre ^a   Ghobrial, Irene ^b   Leleu, Xavier ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Pediatric Medical Neuro Oncology   (United States)

Author keywords

Bortezomib; NFkB inhibitor; Novel therapy; Waldenstrom's macroglobulinemia

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BORTEZOMIB; CLADRIBINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENALIDOMIDE; MELPHALAN; NUCLEOSIDE ANALOG; PREDNISONE; PROTEASOME INHIBITOR; RITUXIMAB; SALINOSPORAMIDE A; THALIDOMIDE; UBIQUITIN;

ADD ON THERAPY; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CLINICAL TRIAL; CONSTIPATION; CYTOTOXICITY; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; HUMAN; INFECTION; LEUKOPENIA; MANTLE CELL LYMPHOMA; MULTIFACTORIAL DELIBITATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEUROPATHIC PAIN; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SATISFACTION; PLASMAPHERESIS; PRACTICE GUIDELINE; REFRACTORY MULITPLE MYELOMA; RELAPSE; REVIEW; SENSORY NEUROPATHY; SIGNAL TRANSDUCTION; SYMPTOM; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

ANIMALS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; HUMANS; PYRAZINES; WALDENSTROM MACROGLOBULINEMIA;

EID: 67649606934     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902800160     Document Type: Review

References (58)

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia. Semin Oncol 2003;30:110-115 (Pubitemid 36506291)
2. Remstein ED, Hanson CA, Kyle RA, et al. Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes and plasma cells. Semin Oncol 2003;30:182-186 (Pubitemid 36506306)
3. Jemal A, Murray T, Ward E, et al. Cancer statistics. CA Cancer J Clin 2005;55:10-30
4. Herrinton LJ, Weiss NS. Incidence of Waldenstrom's macroglobulinemia. Blood 1993;82:3148-3150 (Pubitemid 23334943)
5. Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol 2006;17:488-494 (Pubitemid 43329588)
6. Kristinsson SY, Bjorkholm M, Goldin LR, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. Blood 2008;112:3052-3056
7. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003;102:3759-3764 (Pubitemid 37409398)
8. Kriangkum J, Taylor BJ, Treon SP, et al. Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. Blood 2004;104:2134-2142 (Pubitemid 39297868)
9. Sahota SS, Forconi F, Ottensmeier CH, et al. Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood 2002;100:1505-1507 (Pubitemid 34864315)
10. Schop RF, Van Wier SA, Xu R, et al. 6q deletion discriminates Waldenstrom macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytogenet 2006;169:150-153 (Pubitemid 44382607)
11. Schop RF, Kuehl WM, Van Wier SA, et al. Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood 2002;100:2996-3001
12. Chng WJ, Schop RF, Price-Troska T, et al. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood 2006;108:2755-2763 (Pubitemid 44777013)
13. Leleu X, Eeckhoute J, Jia X, et al. Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood 2008;111:5068-5077
14. Vijay A, Gertz MA. Waldenstrom macroglobulinemia. Blood 2007;109:5096-5103 (Pubitemid 46890523)
15. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617 (Pubitemid 36741588)
16. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498 (Pubitemid 41007864)
17. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917
18. Richardson PG, Mitsiades C, Ghobrial I, Anderson K. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Curr Opin Oncol 2006;18:598-608 (Pubitemid 44427634)
19. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-2520
20. Ryan DP, O'neil BH, Supko JG, et al. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer 2006;107:2688-2697
21. Lu C, Gallegos R, Li P, et al. Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes. Drug Metab Dispos 2006;34:702-708
22. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: US FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003;8:508-513 (Pubitemid 37467365)
23. Mulkerin D, Remick S, Ramanathan R, et al. A dose-escalating and pharmacologic study of bortezomib in adult cancer patients with impaired renal function [abstract 2032]. J Clin Oncol 2006;24(Suppl 18):87
24. Jagannath S, Barlogie B, Berenson JR, et al. Bortezomib in recurrent and/or refractory multiple myeloma. Cancer 2005;103:1195-1200
25. De Duve C, Gianetto R, Appelmans F, Wattiaux R. Enzymic content of the mitochondria fraction. Nature 1953;172:1143-1144
26. Gianetto R, De Duve C. Tissue fractionation studies. 4. Comparative study of the binding of acid phosphatase, beta-glucuronidase and cathepsin by rat-liver particles. Biochem J 1955;59:433-438
27. Goldknopf IL, Busch H. Isopeptide linkage between nonhistone and histone 2A polypeptides of chromosomal conjugate-protein A24. Proc Natl Acad Sci USA 1977;74:864-868 (Pubitemid 8068703)
28. Hershko A, Ciechanover A, Heller H, et al. Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis. Proc Natl Acad Sci USA 1980;77:1783-1786
29. Hough R, Pratt G, Rechsteiner M. Ubiquitin-lysozyme conjugates. Identification and characterization of an ATP-dependent protease from rabbit reticulocyte lysates. J Biol Chem 1986;261:2400-2408 (Pubitemid 17205179)
30. Waxman L, Fagan JM, Goldberg AL. Demonstration of two distinct high molecular weight proteases in rabbit reticulocytes, one of which degrades ubiquitin conjugates. J Biol Chem 1987;262:2451-2457
31. Peters JM, Franke WW, Kleinschmidt JA. Distinct 19 S and 20 S subcomplexes of the 26 S proteasome and their distribution in the nucleus and the cytoplasm. J Biol Chem 1994;269:7709-7718 (Pubitemid 24217985)
32. Nandi D, Tahiliani P, Kumar A, Chandu D. The ubiquitin-proteasome system. J Biosci 2006;31:137-155
33. Liu CW, Li X, Thompson D, et al. ATP binding and ATP hydrolysis play distinct roles in the function of 26S proteasome. Mol Cell 2006;24:39-50 (Pubitemid 44466684)
34. Ciechanover A, Schwartz AL. The ubiquitin-mediated proteolytic pathway: mechanisms of recognition of the proteolytic substrate and involvement in the degradation of native cellular proteins. FASEB J 1994;8:182-191 (Pubitemid 24067141)
35. Perkins ND. The Rel/NF-kappa B family: friend and foe. Trends Biochem Sci 2000;25:434-440
36. Karin M, Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol 2000;12:85-98 (Pubitemid 30114019)
37. Roccaro AM, Vacca A, Ribatti D. Bortezomib in the treatment of cancer. Recent Patents Anticancer Drug Discov 2006;1:397-403
38. Roccaro AM, Leleu X, Sacco A, et al. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2008;111:4752-4763
39. Pangalis GA, Kyrtsonis MC, Vassilakopoulos TP, et al. Immunotherapeutic and immunoregulatory drugs in haematologic malignancies. Curr Top Med Chem 2006;6:1657-1686 (Pubitemid 44323056)
40. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-3076 (Pubitemid 32691956)
41. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-2622 (Pubitemid 29269108)
42. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639-16647 (Pubitemid 34967682)
43. Ghobrial IM, Fonseca R, Gertz MA, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006;133:158-164
44. Fonseca R, Hayman S. Waldenstrom macroglobulinaemia. Br J Haematol 2007;138:700-720 (Pubitemid 47313215)
45. Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood 2006;107:3442-3446
46. Leleu X, Jia X, Runnels J, et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2007;110(13):4417-4426
47. Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009;27:250-255
48. Lin P, Mansoor A, Bueso-Ramos C, et al. Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Clinicopathologic features of 12 cases. Am J Clin Pathol 2003;120:246-253 (Pubitemid 37046359)
49. Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer 2004;101:2593-2598
50. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib. Haematologica 2005;90:1655-1658 (Pubitemid 41814990)
51. Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1570-1575 (Pubitemid 46733084)
52. Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007;13:3320-3325 (Pubitemid 46944918)
53. Treon S, Soumerai JD, Patterson CJ, et al. Bortezomib, dexamethasone and rituximab (BDR) is a highly active regimen in the primary therapy of Waldenstrom's macroglobulinemia: planned interim results of WMCTG clinical trial 05-180 [ASH annual meeting abstracts]. Blood 2006;108:2765
54. Agathocleous AJ, Radford P, Lafon JA, et al. Preliminary results of a phase i/ii study of weekly or twice weekly bortezomib in combination with rituximab, in patients with follicular lymphoma, mantle cell lymphoma and Waldenström's macroglobulinaemia [ASH annual meeting abstracts #2559]. Blood 2007;110
55. Ghobrial IB, Nelson A, Leduc M, et al. Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia: preliminary results [ASH annual meeting abstracts #4494]. Blood 2007;110
56. Alsina M, Trudel S, Vallone M, et al. Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies [ASH annual meeting abstracts #411]. Blood 2007;110
57. Orlowski RZ, Stewart K, Vallone M, et al. Safety and antitumor of the proteasome inhibitor carfilzomib (PR-171) dosed for five consecutive days in hematologic malignancies: phase 1 results [ASH annual meeting abstracts #409]. Blood 2007;110
58. Piva R, Ruggeri B, Williams M, et al. CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 2008;111:2765-2775